Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group
oleh: John H. Edmonson, Louise M. Ryan, Carla I. Falkson, David G. Hicks, Ronald H. Blum
| Format: | Article |
|---|---|
| Diterbitkan: | Hindawi Limited 2003-01-01 |
Deskripsi
Purpose Because we had observed in the synovial sarcoma subgroup of a broad phase III advanced soft tissue sarcoma study a significantly greater objective regression rate from ifosfamide+doxorubicin (88%) than from doxorubicin alone (20%) (P = 0.02), the Eastern Cooperative Oncology Group (ECOG) decided to further assess this two drug combination in a subsequent Phase II study.